These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 18386830)

  • 41. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity.
    Jacinto E; Facchinetti V; Liu D; Soto N; Wei S; Jung SY; Huang Q; Qin J; Su B
    Cell; 2006 Oct; 127(1):125-37. PubMed ID: 16962653
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Estrogen-induced activation of mammalian target of rapamycin is mediated via tuberin and the small GTPase Ras homologue enriched in brain.
    Yu J; Henske EP
    Cancer Res; 2006 Oct; 66(19):9461-6. PubMed ID: 17018601
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Chronic paraplegia-induced muscle atrophy downregulates the mTOR/S6K1 signaling pathway.
    Dreyer HC; Glynn EL; Lujan HL; Fry CS; DiCarlo SE; Rasmussen BB
    J Appl Physiol (1985); 2008 Jan; 104(1):27-33. PubMed ID: 17885021
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Regulatory effects of mammalian target of rapamycin-activated pathways in type I and II interferon signaling.
    Kaur S; Lal L; Sassano A; Majchrzak-Kita B; Srikanth M; Baker DP; Petroulakis E; Hay N; Sonenberg N; Fish EN; Platanias LC
    J Biol Chem; 2007 Jan; 282(3):1757-68. PubMed ID: 17114181
    [TBL] [Abstract][Full Text] [Related]  

  • 45. FAK activity protects nucleostemin in facilitating breast cancer spheroid and tumor growth.
    Tancioni I; Miller NL; Uryu S; Lawson C; Jean C; Chen XL; Kleinschmidt EG; Schlaepfer DD
    Breast Cancer Res; 2015 Mar; 17():47. PubMed ID: 25880415
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of the Activation Status of the Akt/mTOR Signalling Pathway on the Clinical Behaviour of Synovial Sarcoma: Retrospective Analysis of 174 Patients at a Single Institution.
    Li YX; Ding SS; Wen WJ; Han L; Wang HQ; Shi HY
    Cancer Manag Res; 2020; 12():1759-1769. PubMed ID: 32210617
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism.
    Hara K; Yonezawa K; Weng QP; Kozlowski MT; Belham C; Avruch J
    J Biol Chem; 1998 Jun; 273(23):14484-94. PubMed ID: 9603962
    [TBL] [Abstract][Full Text] [Related]  

  • 48. 4′,6-dihydroxy-4-methoxyisoaurone inhibits the HIF-1α pathway through inhibition of Akt/mTOR/p70S6K/4E-BP1 phosphorylation.
    Mi C; Ma J; Shi H; Li J; Wang F; Lee JJ; Jin X
    J Pharmacol Sci; 2014; 125(2):193-201. PubMed ID: 25075425
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Activation of the Akt-mTOR pathway and receptor tyrosine kinase in patients with solitary fibrous tumors.
    Yamada Y; Kohashi K; Fushimi F; Takahashi Y; Setsu N; Endo M; Yamamoto H; Tokunaga S; Iwamoto Y; Oda Y
    Cancer; 2014 Mar; 120(6):864-76. PubMed ID: 24353015
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Endotoxin disrupts the leucine-signaling pathway involving phosphorylation of mTOR, 4E-BP1, and S6K1 in skeletal muscle.
    Lang CH; Frost RA
    J Cell Physiol; 2005 Apr; 203(1):144-55. PubMed ID: 15389631
    [TBL] [Abstract][Full Text] [Related]  

  • 51. TOS motif-mediated raptor binding regulates 4E-BP1 multisite phosphorylation and function.
    Schalm SS; Fingar DC; Sabatini DM; Blenis J
    Curr Biol; 2003 May; 13(10):797-806. PubMed ID: 12747827
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [The relationship of mTOR signaling pathway and histone acetylation in human gastric cancer cell lines].
    Sun DF; Fang JY; Zhang YJ; Tian XQ; Zhu HY; Li EL; Gu WQ; Shen GF
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Aug; 24(4):387-91. PubMed ID: 17680526
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR.
    Dutton A; Reynolds GM; Dawson CW; Young LS; Murray PG
    J Pathol; 2005 Mar; 205(4):498-506. PubMed ID: 15714459
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Distinct role of 4E-BP1 and S6K1 in regulating autophagy and hepatitis B virus (HBV) replication.
    Gao Q; Hou B; Yang H; Jiang X
    Life Sci; 2019 Mar; 220():1-7. PubMed ID: 30690083
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation.
    Wang X; Yue P; Kim YA; Fu H; Khuri FR; Sun SY
    Cancer Res; 2008 Sep; 68(18):7409-18. PubMed ID: 18794129
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Identification of a conserved motif required for mTOR signaling.
    Schalm SS; Blenis J
    Curr Biol; 2002 Apr; 12(8):632-9. PubMed ID: 11967149
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Overexpression of phosphorylated 4E-BP1 predicts for tumor recurrence and reduced survival in cervical carcinoma treated with postoperative radiotherapy.
    Benavente S; Vergés R; Hermosilla E; Fumanal V; Casanova N; García A; Ramón Y Cajal S; Giralt J
    Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1316-22. PubMed ID: 19362787
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The intra-tumor heterogeneity of cell signaling factors in breast cancer: p4E-BP1 and peIF4E are diffusely expressed and are real potential targets.
    Ramon Y Cajal S; De Mattos-Arruda L; Sonenberg N; Cortes J; Peg V
    Clin Transl Oncol; 2014 Nov; 16(11):937-41. PubMed ID: 25060567
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Simultaneous activation of impaired autophagy and the mammalian target of rapamycin pathway in oral squamous cell carcinoma.
    Yin X; Hu L; Feng X; Wang H; Zhang C; Wang H; Wang S
    J Oral Pathol Med; 2019 Sep; 48(8):705-711. PubMed ID: 31132188
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
    deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
    Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.